Lincoln Pharma Financial Statements

Lincoln Pharma (LINCOPH) reported revenue of ₹6.23B in FY2025 with net income of ₹823.46M. Total assets stood at ₹7.97B and free cash flow was ₹739.86M.

Lincoln Pharma Income Statement

Hover the chart icon for year-over-year change.

FY 2021 – FY 2025

Item	Chart	2021	2022	2023	2024	2025
Revenue		4.24B	4.72B	5.10B	5.81B	6.23B
Cost of Rev. Cost of Revenue		-1.98B	-2.19B	-2.41B	-2.78B	-2.91B
Gross Profit		2.26B	2.54B	2.69B	3.02B	3.32B
SGA Sales, General & Admin		-1.39B	-797.15M	-931.60M	-1.03B	-1.12B
Op. Income Operating Income		796.19M	873.93M	800.37M	892.85M	885.94M
PBT Profit Before Tax		837.21M	959.39M	1.00B	1.22B	1.09B
Net Income		622.09M	693.55M	728.99M	933.05M	823.46M
Dil. Shares Diluted Shares		20.00M	20.03M	20.03M	20.03M	20.03M
Diluted EPS		31.10	34.63	36.40	46.58	41.11

Figures in ₹ — millions (M), billions (B), trillions (T). EPS is earnings per share.

Understanding the Income Statement

The income statement shows Lincoln Pharma's revenue and expenses over a period. Revenue minus costs gives gross profit; after operating expenses, interest, and taxes, the remainder is net income. Diluted EPS divides net income by all shares that could exist if options and convertibles were exercised.

Lincoln Pharma Balance Sheet

Hover the chart icon for year-over-year change.

FY 2021 – FY 2025

Item	Chart	2021	2022	2023	2024	2025
Curr. assets Total current assets		3.06B	3.53B	3.67B	4.38B	5.00B
Non-curr. assets Total non-current assets		1.53B	1.82B	2.20B	2.63B	2.97B
Total assets		4.59B	5.34B	5.87B	7.00B	7.97B
Curr. liabilities Total current liabilities		735.46M	904.86M	721.45M	922.77M	1.06B
Non-curr. liab. Total non-current liabilities		101.27M	109.94M	128.01M	151.77M	191.22M
Total liabilities		836.72M	1.01B	849.46M	1.07B	1.25B
Total equity		3.76B	4.33B	5.02B	5.93B	6.72B
Total liab. & eq. Total liabilities & equity		4.59B	5.34B	5.87B	7.00B	7.97B

Figures in ₹ — millions (M), billions (B), trillions (T).

Understanding the Balance Sheet

The balance sheet captures Lincoln Pharma's financial position at a point in time — what it owns (assets), what it owes (liabilities), and the residual value to shareholders (equity). Total assets always equals total liabilities plus equity.

Lincoln Pharma Cash Flow Statement

Hover the chart icon for year-over-year change.

FY 2021 – FY 2025

Item	Chart	2021	2022	2023	2024	2025
Net Income		837.21M	959.39M	1.00B	1.22B	1.09B
Operating CF Cash flow Operating Activities		692.70M	761.32M	392.62M	632.17M	930.16M
Capex Investments in PPE		-87.50M	-455.25M	-142.82M	-394.76M	-190.29M
Investing CF Cash flow Investing Activities		-642.27M	-780.80M	-366.43M	-573.41M	-789.47M
Dividend Paid		0	-30.00M	-30.05M	-30.05M	-36.05M
Financing CF Cash flow Financing Activities		-57.46M	-25.56M	-45.01M	-51.80M	-64.02M
Cash (start) Cash at beginning of period		121.41M	114.38M	69.34M	50.52M	57.47M
Cash (end) Cash at end of period		114.38M	69.34M	50.52M	57.47M	134.14M
FCF Free Cash Flow		605.20M	306.07M	249.80M	237.41M	739.86M

Figures in ₹ — millions (M), billions (B), trillions (T).

Understanding Cash Flow

The cash flow statement tracks how Lincoln Pharma's cash moves through operations, investing, and financing activities. Free cash flow — operating cash minus capital expenditure — shows what is available to return to shareholders.

Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: Mar-2025